Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Core Insights - Monopar Therapeutics Inc. announced new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 for Wilson disease, to be presented at the 150th American Neurological Association Annual Meeting [1][3] Group 1: Efficacy and Safety Data - The analysis pooled efficacy outcomes from three independent clinical trials involving 255 patients, while safety data included a fourth independent clinical trial with 266 patients [2] - Median treatment duration with ALXN1840 was approximately 2.6 years for both efficacy and safety analyses [2] - Statistically significant neurological improvement was sustained over 6 years on the Unified Wilson Disease Rating Scale [6] - Patients who crossed over from standard of care to ALXN1840 showed additional neurological improvement, with many reversing worsened conditions [6] - Statistically significant psychiatric improvement was also sustained over multiple years, measured by the Brief Psychiatric Rating Scale [6] - Neurological benefits were consistently observed across multiple independent studies [6] - The safety profile of ALXN1840 was favorable, with less than 1% of patients experiencing drug-related neurological serious adverse events over more than 645 patient-years [6] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including ALXN1840 for Wilson disease and various radiopharmaceutical programs [4]